Share gains for its cough and cold portfolio and strong demand for probiotics helped to drive up Recordati Industria Chimica & Farmaceutica SPA’s OTC sales at a double-digit rate in 2023.
The Milan, Italy-based firm posted OTC sales up by 10.1% to €331m ($354m) as its winter illness brands flew off...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?